Application of epithelial lining fluid drug concentrations to MIC-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia.

Abstract

INTRODUCTION: Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC-based PK/PD analysis in the lung epithelial lining fluid (ELF). METHODS: In vitro pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing Klebsiella pneumoniae strains. In vivo PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC-based PK/PD analysis was conducted. RESULTS: In vitro, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12-4.30 log CFU/lung, while the combination therapy reduced bacterial counts by -5.93 to -0.234 log CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC(T > MIC) was highly correlated with bacterial reduction. The target T > MICfor maximal effect was estimated to be 29.3 %. CONCLUSIONS: These findings support the utility of MIC-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.